NASDAQ: ALDXAldeyra Therapeutics Inc Stock
$3.98+0.01 (+0.25%)
Updated Apr 18, 2024
ALDX Price
$3.98
Fair Value Price
$2.16
Market Cap
$234.41M
52 Week Low
$1.42
52 Week High
$11.97
P/E
-6.22x
P/B
1.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$37.54M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$30M
Beta
1.45
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ALDX Overview
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALDX ($3.98) is overvalued by 84.48% relative to our estimate of its Fair Value price of $2.16 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALDX ($3.98) is not significantly undervalued (84.48%) relative to our estimate of its Fair Value price of $2.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALDX due diligence checks available for Premium users.
Be the first to know about important ALDX news, forecast changes, insider trades & much more!
ALDX News
Valuation
ALDX fair value
Fair Value of ALDX stock based on Discounted Cash Flow (DCF)
Price
$3.98
Fair Value
$2.16
Overvalued by
84.48%
ALDX ($3.98) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALDX ($3.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.22x
Industry
15.68x
Market
41.33x
ALDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.96x
Industry
5.76x
ALDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALDX's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.8M
Profit Margin
0%
ALDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$148.3M
Liabilities
$28.5M
Debt to equity
0.24
ALDX's short-term assets ($147.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALDX's short-term assets ($147.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALDX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$500.4k
Investing
$0.0
Financing
-$1.0M
ALDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALDX vs Biotech Stocks
Aldeyra Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.